Home News: Pharma
Pharmaceutical Industry News, Drugs, Nutraceuticals, Vitamins, and Related
Learn The Risk Launches New Billboard Campaign in FIVE US Cities Honoring Healthy 2-Year Old Who Died Days After Vaccines
eNewsChannels NEWS: -- This week, the non-profit Learn The Risk launched five billboards on the East Coast, including New York and Boston, honoring Nicholas Catone, a healthy 20-month old boy who lost his life to vaccines. The five-city billboard campaign aims to raise awareness of vaccine side effects, including death.
eNewsChannels NEWS: (IRVING, Texas) -- BioTE(R) Medical announces a forum of medical experts gathering before the Age Management Medicine Group (AMMG) to form consensus on testosterone therapy in women. The AMMG conference runs April 27-30, 2017 in Orlando, Florida.
C Diff Foundation Announces Experts to Gather Nov. 9-10 in Las Vegas about Infection Clostridium difficile
eNewsChannels NEWS: (LAS VEGAS, Nev.) -- C Diff Foundation's 5th Annual International C.diff. Awareness Conference and Health EXPO will be hosted in Las Vegas, Nev. on November 9 & 10, 2017 at UNLV-Thomas and Mack Center. A panel of C. diff. survivors will join world-renowned experts delivering presentations on health care topics pertaining to the most common pathogen identified, a leading healthcare-associated infection (HAI) in U.S. hospitals alone: Clostridium difficile (C.diff.).
eNewsChannels NEWS: (CORTE MADERA, Calif.) -- Dr. Don Harte, chiropractic activist, says Trump's new panel, headed by Chris Christie, to deal with the opioid epidemic, is "philosophically and scientifically dead wrong." Dr. Harte declares, "The reason for this epidemic is clear. Orthopedists and other doctors freely prescribe Oxycontin, Fentanyl, Soma and other opioid drugs, get their patients addicted."
eNewsChannels NEWS: (AURORA, Colo.) -- Extreme Muscle Products (EMP) have announced the launch of its first formulation available for purchase, a product called Q-Meric. EMP is a newly created Colorado-based company focusing on health, wellness and athletic performance, with an emphasis on products that have synergistic effects.
Ruling by USPTO Affirms Patent Claim for Paragon BioTeck’s R-Phenylephrine Hydrochloride Formulation
eNewsChannels NEWS: (PORTLAND, Ore.,) -- Paragon BioTeck, Inc. announces a monumental ruling handed down by the United States Patent and Trademark Office (USPTO) affirming claims made by Paragon in the patent for its R-phenylephrine hydrochloride formulation. Paragon is a privately held pharmaceutical and medical device company specializing in the development and commercialization of ophthalmic pharmaceuticals, devices and therapies.
NEWS: (NEW YORK, N.Y.) National lawfirm Weitz and Luxenberg, P.C., said today it hopes potentially fatal side effects associated with SGLT2 inhibitor drugs will be reported to consumers faster, since people taking these next-generation diabetes medications deserve to be notified of the health dangers shortly after they have been reported to the U.S. Food and Drug Administration (FDA).
NEWS: (BOULDER, Colo.) Terrapin Care Station, with dispensaries in Boulder and Aurora, Colo., begins a new year with the launch of two cannabis products that incorporate innovative packaging design with child resistance, product protection, and portability.
At 34th Annual J.P. Morgan Healthcare Conference, Paragon BioTeck to sponsor reception held by Oregon Bioscience Assoc.
NEWS: Paragon BioTeck, Inc., a privately held pharmaceutical and medical device company, will sponsor a special reception during the J.P. Morgan 2016 Healthcare Conference, being held in San Francisco, Jan. 11-14. The conference, which is now in its 34th year, is an invitation-only event intended to create an environment of collaboration by bringing together stakeholders in the corporate, investor and financial sectors to learn about and explore market and sector trends.
NEWS: Weitz and Luxenberg, P.C., today announced that the firm has expanded the scope of its investigation into SGLT2 inhibitor drug injuries. SGLT2 inhibitor drugs include Invokana and others listed below. This move will allow the nationally known mass tort law and personal injury firm to focus on cases where people taking SGLT2 inhibitors were hospitalized after developing urosepsis (serious infection of the blood) or pyelonephritis (infection of the kidneys) from SGLT2 inhibitor-associated urinary tract infections.